CUMBERLAND PHARMACEUTICALS INC Earnings Per Share Disclosure
| 2024 | 2023 | |||||||||||||
| Numerator: | ||||||||||||||
| Net loss | $ | (6,443,715) | $ | (6,330,766) | ||||||||||
| Net (income) loss at subsidiary attributable to noncontrolling interests | (36,055) | 51,446 | ||||||||||||
| Net loss attributable to common shareholders | $ | (6,479,770) | $ | (6,279,320) | ||||||||||
| Denominator: | ||||||||||||||
| Weighted-average shares outstanding – basic | 14,060,272 | 14,298,774 | ||||||||||||
| Weighted-average shares outstanding – diluted | 14,060,272 | 14,298,774 | ||||||||||||
| 2024 | 2023 | |||||||||||||
| Anti-dilutive shares and options | 611,353 | 452,224 | ||||||||||||
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.